LMR Partners’s Ovid Therapeutics OVID Stock Holding History

LMR Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-26,199	Closed	-$102K	–	1145
2021 Q2	$102K	Buy	+26,199	New	+$103K	﹤0.01%	860

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

LMR Partners's OVID Position: Q3 2021 in Review

LMR Partners sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 26,199 shares — an estimated $102K sold.

LMR Partners first reported a position in OVID in Q2 2021 and held it in 1 quarter. The position peaked at $102K in Q2 2021. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

LMR Partners reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 26,199 Ovid Therapeutics shares in Q3 2021, an estimated $102K.
LMR Partners first reported a position in Ovid Therapeutics in Q2 2021 and held it in 1 quarter.
LMR Partners's Ovid Therapeutics position peaked at $102K in Q2 2021.
72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.